Kidney Cancer

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

An international study of nearly 2,000 patients with renal cell carcinoma exposed many unmet needs across all stages of disease.

Patients with advanced renal cell carcinoma have new first-line therapy options.

The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.

With the growing price of cancer treatment, researchers evaluated the cost-effectiveness of the new standard-of-care in frontline metastatic renal cell carcinoma.

Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.

With patient resistance to single-agent immunotherapies in the treatment of advanced renal cell carcinoma, new combination therapies are needed in the frontline setting.

A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.

The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.

The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma – the most common type of kidney cancer.

There is still work to do in the field of molecular diagnosis for renal cell carcinoma, according to David I. Quinn, MBBS, Ph.D., FRACP, FACP.

An expert discusses the evolving treatments for renal cell carcinoma (RCC) over the last decade, as well as the future role of immunotherapies for patients with RCC.

In conjunction with Kidney Cancer Awareness Month, learn more about risk factors and treatment options for the disease.

Frontline use of Bavencio (avelumab) plus Inlyta (axitinib) significantly improved progression-free survival compared with the standard of care in patients with advanced renal cell carcinoma.

CURE® spoke with a researcher from the American Cancer Society to examine temporal trends of obesity-related cancers in younger adults.

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.

The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).

Meeting combined exercise guidelines improved quality of life in kidney cancer survivors; however, few individuals reported that they actually follow such guidelines.

Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.

Certain factors – such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma.

People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.

Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.

We've got a sneak peek at what’s inside our Fall 2018 issue.

Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.

Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.

Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.

More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.

Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.